Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension

ical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension Review (2258) Total Article Views Authors: Shuster JE, Bleske BE, Dorsch MP Published Date June 2012 Volume 2012:8 Pages 381 - 387 DOI: http://dx.doi.org/10.2147/VHRM.S22583 Received: 21 January 2012 Accepted: 01 March 2012 Published: 13 June 2012 Jerrica E Shuster,1,2 Barry E Bleske,1,2 Michael P Dorsch1,2 1University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA; 2College of Pharmacy, University of Michigan, Ann Arbor, MI, USA Abstract: Azilsartan–chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique because it is the first to partner an ARB with this, possibly more effective, diuretic. This review will address trials involving both components of this drug, as well as phase III trials involving the fixed-combination product. The article will also discuss the benefit of combination therapy in the treatment of hypertension.